{"log_id": 6313991919386646455, "direction": 0, "words_result_num": 77, "words_result": [{"probability": {"variance": 0.00084, "average": 0.984219, "min": 0.919581}, "location": {"width": 92, "top": 78, "height": 18, "left": 110}, "words": "系统器官分类"}, {"probability": {"variance": 1.9e-05, "average": 0.996146, "min": 0.988898}, "location": {"width": 68, "top": 75, "height": 22, "left": 459}, "words": "不良反应"}, {"probability": {"variance": 0.001192, "average": 0.984855, "min": 0.827795}, "location": {"width": 704, "top": 102, "height": 25, "left": 105}, "words": "各类损伤、中毒及手术并发症未知*椎管内或者硬膜外血肿(见【禁忌】和【注意事项】"}, {"probability": {"variance": 7.6e-05, "average": 0.995026, "min": 0.970612}, "location": {"width": 169, "top": 134, "height": 20, "left": 123}, "words": "根据现有数据无法确定"}, {"probability": {"variance": 6.4e-05, "average": 0.996451, "min": 0.954773}, "location": {"width": 677, "top": 166, "height": 24, "left": 130}, "words": "出血风险取决于剂量。大多数出血为轻度。有严重出血的报告,且其中有些病例是致命性的"}, {"probability": {"variance": 3e-06, "average": 0.9988, "min": 0.993498}, "location": {"width": 407, "top": 188, "height": 21, "left": 130}, "words": "肝素制品可引起醛固酮减少症,进而可导致血浆钾升高"}, {"probability": {"variance": 0.005565, "average": 0.987042, "min": 0.481737}, "location": {"width": 797, "top": 207, "height": 25, "left": 131}, "words": "在罕见情况下,可能会出现具有临床意义的高钟血症,尤其是在慢性肾衰竭和糖尿病患者中(见【注意事项"}, {"probability": {"variance": 6.6e-05, "average": 0.996562, "min": 0.946419}, "location": {"width": 845, "top": 229, "height": 24, "left": 131}, "words": "使用肝素进行长期治疗有患骨质疏松症的风险。尽管使用达肝素尚未观察到此类病例,但仍不能排除患骨质疏松症"}, {"probability": {"variance": 0.054393, "average": 0.864138, "min": 0.46019}, "location": {"width": 60, "top": 271, "height": 21, "left": 138}, "words": "儿童人群"}, {"probability": {"variance": 4.9e-05, "average": 0.996583, "min": 0.955984}, "location": {"width": 704, "top": 292, "height": 22, "left": 130}, "words": "不良反应的频率、类型和严重程度在儿童中预计和成人相同。达肝素长期给药的安全性尚未确定"}, {"probability": {"variance": 4e-06, "average": 0.996679, "min": 0.993891}, "location": {"width": 52, "top": 335, "height": 22, "left": 92}, "words": "【禁忌】"}, {"probability": {"variance": 1.6e-05, "average": 0.996759, "min": 0.987159}, "location": {"width": 135, "top": 355, "height": 23, "left": 131}, "words": "以下情况禁用本品"}, {"probability": {"variance": 0.015775, "average": 0.962301, "min": 0.487722}, "location": {"width": 490, "top": 375, "height": 25, "left": 137}, "words": "对达肝素钠、任一辅料、其它低分子肝素和/或肝素或猪肉制品过敏"}, {"probability": {"variance": 0.00307, "average": 0.981053, "min": 0.702659}, "location": {"width": 464, "top": 398, "height": 21, "left": 129}, "words": "确定或怀疑患有肝素诱导的免疫介导型血小板减少(Ⅱ型)病史"}, {"probability": {"variance": 7.4e-05, "average": 0.991794, "min": 0.976695}, "location": {"width": 153, "top": 419, "height": 19, "left": 130}, "words": "急性胃十二指肠溃疡"}, {"probability": {"variance": 2e-06, "average": 0.998468, "min": 0.994314}, "location": {"width": 187, "top": 439, "height": 21, "left": 130}, "words": "脑出血或其他活动性出血"}, {"probability": {"variance": 5e-06, "average": 0.997926, "min": 0.993767}, "location": {"width": 150, "top": 460, "height": 20, "left": 130}, "words": "严重的凝血系统疾病"}, {"probability": {"variance": 1.4e-05, "average": 0.99751, "min": 0.989004}, "location": {"width": 119, "top": 480, "height": 19, "left": 130}, "words": "脓毒性心内膜炎"}, {"probability": {"variance": 1e-06, "average": 0.998937, "min": 0.996283}, "location": {"width": 305, "top": 499, "height": 22, "left": 131}, "words": "中枢神经系统、眼部及耳部的损伤和手术"}, {"probability": {"variance": 0.000608, "average": 0.991931, "min": 0.830949}, "location": {"width": 1007, "top": 520, "height": 25, "left": 130}, "words": "接受大剂量达肝素(例如治疗急性深静脉血栓、肺动脉栓塞以及不稳定性冠状动脉疾病)时,禁止实施脊椎或硬膜外麻醉或椎管穿刺(见"}, {"probability": {"variance": 0.001116, "average": 0.984171, "min": 0.909494}, "location": {"width": 100, "top": 541, "height": 21, "left": 109}, "words": "注意事项】)"}, {"probability": {"variance": 2e-06, "average": 0.998401, "min": 0.995799}, "location": {"width": 81, "top": 582, "height": 22, "left": 101}, "words": "注意事项】"}, {"probability": {"variance": 0.000998, "average": 0.991088, "min": 0.780772}, "location": {"width": 813, "top": 602, "height": 24, "left": 131}, "words": "禁止肌肉注射本品。由于存在血肿风险,当24小时达肝素钠剂量超过5000IU时,应避免肌肉注射其他药物制剂"}, {"probability": {"variance": 0.021327, "average": 0.899189, "min": 0.648523}, "location": {"width": 67, "top": 626, "height": 19, "left": 96}, "words": "出血风险"}, {"probability": {"variance": 2.6e-05, "average": 0.997483, "min": 0.965241}, "location": {"width": 1009, "top": 643, "height": 25, "left": 130}, "words": "本品慎用于血小板减少和血小板功能障碍、严重肝肾功能不全、未控制的高血压、高血压性或糖尿病性视网膜病以及已知对肝素制剂和"}, {"probability": {"variance": 6e-06, "average": 0.998276, "min": 0.988642}, "location": {"width": 1048, "top": 664, "height": 24, "left": 96}, "words": "或低分子肝素制剂过敏的患者。近期接受手术的患者及存在疑似可增加出血风险的其他疾病的患者在使用大剂量达肝素钠时亦应慎重,比如那"}, {"probability": {"variance": 3e-06, "average": 0.998597, "min": 0.992291}, "location": {"width": 591, "top": 685, "height": 23, "left": 96}, "words": "些需要进行急性深静脉血栓、肺动脉栓塞或者不稳定性冠状动脉疾病治疗的患者"}, {"probability": {"variance": 4.2e-05, "average": 0.992947, "min": 0.979858}, "location": {"width": 136, "top": 706, "height": 22, "left": 97}, "words": "硬膜外或脊椎麻醉"}, {"probability": {"variance": 0.000573, "average": 0.993299, "min": 0.834311}, "location": {"width": 789, "top": 726, "height": 23, "left": 128}, "words": "进行椎管内麻醉(硬膜外/脊椎麻醉)或椎管穿刺时使用低分子肝素的患者(包括计划接受抗凝治疗的患者"}, {"probability": {"variance": 9e-06, "average": 0.997316, "min": 0.990359}, "location": {"width": 190, "top": 728, "height": 23, "left": 953}, "words": "存在出现硬膜外或椎管内"}, {"probability": {"variance": 0.002962, "average": 0.991702, "min": 0.571119}, "location": {"width": 1047, "top": 745, "height": 25, "left": 96}, "words": "血肿的风险,从而引起不同程度的神经损伤,包括长期性或永久性麻痹。当术后留置硬膜外导管或联合使用影响止血的药物(如非甾体抗炎"}, {"probability": {"variance": 0.001303, "average": 0.991507, "min": 0.736881}, "location": {"width": 894, "top": 768, "height": 21, "left": 94}, "words": "药、血小板抑制剂或其他抗凝剂)时,会使发生这些事件的风险升高。创伤性或反复性硬膜外或脊髓穿刺也会使风险升高"}, {"probability": {"variance": 0.000198, "average": 0.995476, "min": 0.897257}, "location": {"width": 1014, "top": 789, "height": 22, "left": 130}, "words": "在脊椎或硬膜外麻醉期间使用达肝素钠注射液时,为降低出血风险,最好在达肝素钠注射液的抗凝血作用处于最小时插入或移去导管。当"}, {"probability": {"variance": 0.000142, "average": 0.994667, "min": 0.925319}, "location": {"width": 1037, "top": 809, "height": 21, "left": 101}, "words": "达肝素钠注射液用来预防深静脉血栓时,应在最后一次给药12小时后再插入或移去导管。若患者出血风险增高,则需在最后一次给药至少24小"}, {"probability": {"variance": 0.002126, "average": 0.990216, "min": 0.650172}, "location": {"width": 969, "top": 830, "height": 24, "left": 95}, "words": "时后再插入或移去导管。使用本品根治性治疗急性深静脉血栓时严禁实施任何硬膜外或脊椎麻醉或穿刺(见【用法用量】和【禁忌】"}, {"probability": {"variance": 2.2e-05, "average": 0.997588, "min": 0.981564}, "location": {"width": 395, "top": 851, "height": 19, "left": 129}, "words": "导管去除至少4小时后才可使用下一剂达肝素钠注射液"}, {"probability": {"variance": 0.002513, "average": 0.990236, "min": 0.609597}, "location": {"width": 1009, "top": 870, "height": 23, "left": 130}, "words": "当医生决定在硬膜外/脊椎麻醉或椎管穿刺前使用抗凝剂时,需要特别小心并密切监控,以便及时发现任何神经体征或症状,比如背部疼"}, {"probability": {"variance": 6.2e-05, "average": 0.996258, "min": 0.962628}, "location": {"width": 1048, "top": 891, "height": 23, "left": 94}, "words": "痛、感觉或运动障碍(下肢麻木或无力,膀胱功能失调)。护士应接受特别培训以便及时识别神经功能失调的症状。应要求患者一旦出现神经"}, {"probability": {"variance": 1.3e-05, "average": 0.998078, "min": 0.980626}, "location": {"width": 811, "top": 912, "height": 23, "left": 95}, "words": "异常症状要及时告知医生。如果怀疑出现脊柱内血肿的体征或症状,需要给予紧急诊断或治疗,包括脊髓减压"}, {"probability": {"variance": 0, "average": 0.999364, "min": 0.99807}, "location": {"width": 100, "top": 935, "height": 20, "left": 97}, "words": "血小板减少症"}, {"probability": {"variance": 0.000229, "average": 0.993525, "min": 0.923736}, "location": {"width": 708, "top": 953, "height": 24, "left": 129}, "words": "由于存在血小板减少的风险,建议在开始达肝素治疗前做血小板计数检查并在治疗期间定期复查"}, {"probability": {"variance": 0.002722, "average": 0.991053, "min": 0.592763}, "location": {"width": 1015, "top": 974, "height": 24, "left": 130}, "words": "对于快速出现的血小板减少,或在使用本品或其它低分子肝素和/或肝素的体外实验中显示抗血小板抗体阳性或结果未知的严重血小板减"}, {"probability": {"variance": 0.022739, "average": 0.936987, "min": 0.42669}, "location": {"width": 230, "top": 996, "height": 20, "left": 96}, "words": "少(0000/),需特别注意"}, {"probability": {"variance": 1e-06, "average": 0.999151, "min": 0.994885}, "location": {"width": 357, "top": 1015, "height": 23, "left": 130}, "words": "当出现上述血小板减少时应停止治疗(见【禁忌"}, {"probability": {"variance": 0.00897, "average": 0.951516, "min": 0.762108}, "location": {"width": 81, "top": 1016, "height": 20, "left": 469}, "words": "忌1)。只"}, {"probability": {"variance": 1.7e-05, "average": 0.998081, "min": 0.977976}, "location": {"width": 589, "top": 1015, "height": 23, "left": 534}, "words": "只有在体外实验中显示普通肝素不会引起患者血小板聚合反应才可重新开始治疗"}, {"probability": {"variance": 1.7e-05, "average": 0.998125, "min": 0.979713}, "location": {"width": 1046, "top": 1035, "height": 24, "left": 96}, "words": "治疗开始后,每周至少做2次血小板计数检查,尤其是治疗初期的前三周。重要说明:肝素所引起的型血小板减少症不应与早期术后血小板减"}, {"probability": {"variance": 8.1e-05, "average": 0.99384, "min": 0.978288}, "location": {"width": 67, "top": 1058, "height": 20, "left": 97}, "words": "少症混淆"}, {"probability": {"variance": 0.00621, "average": 0.958803, "min": 0.767381}, "location": {"width": 99, "top": 1077, "height": 22, "left": 129}, "words": "监测抗Xa水平"}, {"probability": {"variance": 0.002404, "average": 0.987089, "min": 0.686099}, "location": {"width": 1014, "top": 1097, "height": 24, "left": 128}, "words": "通常不需监测达肝素的抗凝效果,但对于特定患者人群,如儿童;肾衰竭患者;或极瘦或重度肥胖患者,孕妇,或出血或血栓再形成风险"}, {"probability": {"variance": 7.7e-05, "average": 0.995185, "min": 0.969315}, "location": {"width": 187, "top": 1119, "height": 21, "left": 95}, "words": "增高的患者,应考虑监测"}, {"probability": {"variance": 0.000779, "average": 0.992275, "min": 0.783922}, "location": {"width": 1013, "top": 1138, "height": 23, "left": 131}, "words": "本品对凝血时间测定(以活化部分凝血酶时间,APTT测量)只有中度延长作用。由于此项测定对达肝素的活性相对不敏感,因此不应使"}, {"probability": {"variance": 0.000736, "average": 0.991398, "min": 0.831061}, "location": {"width": 802, "top": 1160, "height": 21, "left": 97}, "words": "用。为延长APTT而增加剂量可能导致药物过量和出血。建议通过功能性抗Xa测定进行出血风险的实验室监测"}, {"probability": {"variance": 0.000136, "average": 0.996821, "min": 0.916492}, "location": {"width": 1013, "top": 1182, "height": 22, "left": 132}, "words": "不稳定型冠状动脉疾病,如:不稳定型心绞痛和非Q波型心肌梗死的患者若发生透壁性心肌梗死,可进行溶栓治疗。没有必要因进行溶栓"}, {"probability": {"variance": 2.3e-05, "average": 0.998102, "min": 0.979825}, "location": {"width": 271, "top": 1202, "height": 21, "left": 96}, "words": "而停用本品,但可能增加出血的危险"}, {"probability": {"variance": 0.046538, "average": 0.870086, "min": 0.496571}, "location": {"width": 66, "top": 1226, "height": 18, "left": 97}, "words": "高钟血症"}, {"probability": {"variance": 9.8e-05, "average": 0.996631, "min": 0.932476}, "location": {"width": 1015, "top": 1241, "height": 25, "left": 128}, "words": "肝素可抑制肾上腺分泌醛固酮,导致高血钾症,特别是患有糖尿病、慢性肾功能衰竭、已存在的代谢性酸中毒、血钾浓度上升或正在服用"}, {"probability": {"variance": 0.000153, "average": 0.994231, "min": 0.928711}, "location": {"width": 1029, "top": 1264, "height": 22, "left": 96}, "words": "保钾药物的患者更需注意。高钾血症风险似乎会随治疗持续时间而增加,但通常是可逆的。肝素治疗开始前应对风险患者人群进行血钾测量"}, {"probability": {"variance": 6.3e-05, "average": 0.996514, "min": 0.96041}, "location": {"width": 410, "top": 1285, "height": 20, "left": 96}, "words": "并在此后定期监测,特别是在治疗持续时间超过约7天时"}, {"probability": {"variance": 8e-05, "average": 0.98789, "min": 0.976444}, "location": {"width": 67, "top": 1307, "height": 18, "left": 130}, "words": "血液透析"}, {"probability": {"variance": 0.004551, "average": 0.981268, "min": 0.52755}, "location": {"width": 997, "top": 1325, "height": 22, "left": 146}, "words": "般情况下,长期接受血液透析的患者应用本品时,需要调整剂量的次数更少,因而监测抗xa水平的次数也更少。接受急性血液透析的患"}, {"probability": {"variance": 0.002032, "average": 0.985218, "min": 0.778238}, "location": {"width": 375, "top": 1347, "height": 21, "left": 96}, "words": "者可能更不稳定,应对抗Xa水平进行更全面的监测"}, {"probability": {"variance": 0.000204, "average": 0.993841, "min": 0.949105}, "location": {"width": 184, "top": 1364, "height": 23, "left": 98}, "words": "与其它抗凝剂的可互换性"}, {"probability": {"variance": 0.000568, "average": 0.993656, "min": 0.827287}, "location": {"width": 1014, "top": 1385, "height": 24, "left": 131}, "words": "简单的剂量参比测试无法表征低分子肝素、普通肝素或合成多糖的不同制剂的生物活性。因为不同的低分子肝素制剂具有不同的特性,有"}, {"probability": {"variance": 0.000135, "average": 0.995235, "min": 0.946777}, "location": {"width": 456, "top": 1406, "height": 24, "left": 96}, "words": "必要调整剂量。因此,应特别注意并遵守相应产品的使用方法"}, {"probability": {"variance": 1.9e-05, "average": 0.997265, "min": 0.983069}, "location": {"width": 357, "top": 1429, "height": 21, "left": 129}, "words": "达肝素钠注射液对驾驶或机械操作能力没有影响"}, {"probability": {"variance": 0.00024, "average": 0.990728, "min": 0.948629}, "location": {"width": 185, "top": 1470, "height": 21, "left": 98}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.000178, "average": 0.981045, "min": 0.967716}, "location": {"width": 27, "top": 1493, "height": 17, "left": 103}, "words": "壬娠"}, {"probability": {"variance": 2.3e-05, "average": 0.998035, "min": 0.963181}, "location": {"width": 1013, "top": 1510, "height": 22, "left": 132}, "words": "现有经验未发现孕妇接受低分子肝素治疗会损害胚胎或胎儿的任何证据。到目前为止,有关在妊娠期使用低分子肝素的对照研究数量非常"}, {"probability": {"variance": 4e-06, "average": 0.998046, "min": 0.994476}, "location": {"width": 185, "top": 1533, "height": 20, "left": 96}, "words": "有限。达肝素不通过胎盘"}, {"probability": {"variance": 0.002359, "average": 0.985214, "min": 0.671526}, "location": {"width": 1014, "top": 1553, "height": 21, "left": 130}, "words": "正在使用大剂量抗凝剂治疗的妇女在分娩期间绝对禁止接受硬膜外麻醉(见【禁忌】)。在处于妊娠晚期的孕妇中测得达肝素抗Xa的半衰"}, {"probability": {"variance": 9.1e-05, "average": 0.994665, "min": 0.971599}, "location": {"width": 102, "top": 1574, "height": 21, "left": 95}, "words": "期为4至5小时"}, {"probability": {"variance": 5.3e-05, "average": 0.995699, "min": 0.965272}, "location": {"width": 499, "top": 1593, "height": 23, "left": 130}, "words": "动物试验未发现达肝素具有任何致畸性或胚胎毒性(见【药理毒理】"}, {"probability": {"variance": 0, "average": 0.99981, "min": 0.99981}, "location": {"width": 28, "top": 1616, "height": 20, "left": 101}, "words": "乳"}, {"probability": {"variance": 0.003246, "average": 0.987102, "min": 0.599563}, "location": {"width": 1014, "top": 1634, "height": 22, "left": 131}, "words": "少量达肝素钠会进入乳汁。到目前为止,研究表明乳汁中的抗凝血因子Xa浓度为血浆浓度的2%到8%(15名妇女,哺乳期第3至第5天,皮"}, {"probability": {"variance": 4e-06, "average": 0.998659, "min": 0.991957}, "location": {"width": 1050, "top": 1653, "height": 24, "left": 97}, "words": "下注射达肝素后2至3小时)。对婴儿不大可能产生抗凝作用,尽管如此,只有当治疗对母亲的益处大于对婴儿的潜在风险时,才能在哺乳期使"}, {"probability": {"variance": 1e-06, "average": 0.998741, "min": 0.997785}, "location": {"width": 67, "top": 1679, "height": 18, "left": 97}, "words": "用达肝素"}], "language": 3}